Physiological role of endothelin-1in flow-mediated vasodilatation in humans and impact of cardiovascular risk factors

Journal of Hypertension

Volumn 35, Issue 6, 2017, Pages 1204-1212

  Bellien, Jérémy ^a,b,c   Iacob, Michèle ^a,b   Monteil, Christelle ^c,d   Rémy Jouet, Isabelle ^b,c   Roche, Clothilde ^b,c   Duflot, Thomas ^a,b,c   Vendeville, Cathy ^d   Gutierrez, Laurence ^b   Thuillez, Christian ^a,b,c   Richard, Vincent ^a,b,c   Joannidès, Robinson ^a,b,c  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITY OF ROUEN   (France)

^d Envtl   (France)

Author keywords

Endothelin type A receptor; Endothelin type B receptor; Endothelin 1; Endothelium; Flow mediated dilatation

Indexed keywords

CHOLESTEROL; CREATININE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; GLUCOSE; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITRIC OXIDE; SODIUM CHLORIDE; TRIACYLGLYCEROL; CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; OLIGOPEPTIDE; PIPERIDINE DERIVATIVE;

ADULT; ARTICLE; BLOOD FLOW; BLOOD VISCOSITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FLOW-MEDIATED DILATION TEST; GLUCOSE BLOOD LEVEL; HEATING; HUMAN; HUMAN EXPERIMENT; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIAL ARTERY; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; CARDIOVASCULAR DISEASE; DRUG EFFECTS; HEMODYNAMICS; METABOLISM; PHYSIOLOGY; RISK FACTOR; YOUNG ADULT;

ADULT; CARDIOVASCULAR DISEASES; ENDOTHELIN A RECEPTOR ANTAGONISTS; ENDOTHELIN B RECEPTOR ANTAGONISTS; ENDOTHELIN RECEPTOR ANTAGONISTS; ENDOTHELIN-1; FEMALE; HEMODYNAMICS; HUMANS; MALE; NITRIC OXIDE; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PIPERIDINES; RISK FACTORS; VASODILATION; YOUNG ADULT;

EID: 85018349654     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001307     Document Type: Article

References (34)

1. Joannides R, Haefeli W, Linder L, Richard V, Bakkali EH, Thuillez C, Lüscher T. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91:1314-1319.
2. Bellien J, Iacob M, Remy-Jouet I, Lucas D, Monteil C, Gutierrez L, et al. Epoxyeicosatrienoic acids contribute with alteredNO and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension. Circulation 2012; 125:1266-1275.
3. Lorthioir A, Joannides R, Remy-Jouet I, Freguin-Bouilland C, Iacob M, Roche C, et al. Polycystin deficiency induces dopamine-reversible alterations in flow-mediated dilatation and vascular NO release in humans. Kidney Int 2015; 87:465-472.
4. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
5. Thorin E, Webb DJ. Endothelium-derived endothelin-1. Pflugers Arch 2010; 459:951-958.
6. Mazzuca MQ, Khalil RA. Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem Pharmacol 2012; 84:147-162.
7. Kyriakides ZS, Kremastinos DT, Bofilis E, Tousoulis D, Antoniadis A, Webb DJ. Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography. Heart 2000; 84:176-182.
8. Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001; 104:1114-1118.
9. Halcox JP, Nour KR, Zalos G, Quyyumi AA. Endogenous endothelin in human coronary vascular function: differential contribution of endothelin receptor types A and B. Hypertension 2007; 49:1134-1141.
10. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344:852-854.
11. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97:752-756.
12. Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb DJ. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999; 33:581-585.
13. Spratt JC, Goddard J, Patel N, Strachan FE, Rankin AJ, Webb DJ. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol 2001; 134:648-654.
14. Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO 3rd, Panza JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999; 33:753-758.
15. Van Guilder GP, Westby CM, Greiner JJ, Stauffer BL, DeSouza CA. Endothelin-1 vasoconstrictor tone increases with age in healthy men but can be reduced by regular aerobic exercise. Hypertension 2007; 50:403-409.
16. Stauffer BL, Westby CM, Greiner JJ, Van Guilder GP, Desouza CA. Sex differences in endothelin-1-mediated vasoconstrictor tone in middleaged and older adults. Am J Physiol Regul Integr Comp Physiol 2010; 298:R261-R265.
17. Spieker LE, Lüscher TF, Noll G. ETA receptors mediate vasoconstriction of large conduit arteries during reduced flow in humans. J Cardiovasc Pharmacol 2003; 42:315-318.
18. Spieker LE, Hürlimann D, Ruschitzka F, Corti R, Enseleit F, Shaw S, et al. Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation 2002; 105:2817-2820.
19. Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 1992; 50:247-255.
20. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A 1994; 91:4892-4896.
21. Ling L, Maguire JJ, Davenport AP. Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer. Br J Pharmacol 2013; 168:283-295.
22. Halili L, Singh MS, Fujii N, Alexander LM, Kenny GP. Endothelin-1 modulates methacholine-induced cutaneous vasodilatation but not sweating in young human skin. J Physiol 2016; 594:3439-3452.
23. Böhm F, Pernow J, Lindström J, Ahlborg G. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) 2003; 104:143-151.
24. Morawietz H, Talanow R, Szibor M, Rueckschloss U, Schubert A, Bartling B, et al. Regulation of the endothelin system by shear stress in human endothelial cells. J Physiol 2000; 525:761-777.
25. Dupuis J, Rouleau JL, Cernacek P. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. Circulation 1998; 98:1684-1687.
26. Dupuis J, Cernacek P, Tardif JC, Stewart DJ, Gosselin G, Dyrda I, et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 1998; 135:614-620.
27. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases: A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23:233-246.
28. McEniery CM, Wilkinson IB, Jenkins DG, Webb DJ. Endogenous endothelin-1 limits exercise-induced vasodilation in hypertensive humans. Hypertension 2002; 40:202-206.
29. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA. Increased activity of endogenous endothelin in patients with hypercholesterolemia. J Am Coll Cardiol 2000; 36:1483-1488.
30. Brar V, Gill S, Cardillo C, Tesauro M, Panza JA, Campia U. Sex-specific effects of cardiovascular risk factors on endothelium-dependent dilation and endothelin activity in middle-aged women and men. PLoS One 2015; 10:e0121810.
31. Dagassan PH, Breu V, Clozel M, Künzli A, Vogt P, Turina M, et al. Upregulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 1996; 27:147-153.
32. Sutherland AJ, Nataatmadja MI, Walker PJ, Cuttle L, Garlick RB, West MJ. Vascular remodeling in the internal mammary artery graft and association with in situ endothelin-1 and receptor expression. Circulation 2006; 113:1180-1188.
33. Dimitrijevic I, Edvinsson ML, Chen Q, Malmsjö M, Kimblad PO, Edvinsson L. Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease. BMC Cardiovasc Disord 2009; 9:40.
34. Kakoki M, Hirata Y, Hayakawa H, Tojo A, Nagata D, Suzuki E, et al. Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. Circulation 1999; 99:1242-1248.